It's not uncommon for biotechs to go quiet for long stretches of time,
particularly when they are basically one-product companies with little
incremental data on the way. In the case of YM Biosciences (YMI),
though, shareholders have reason to be a little edgy about the lack of
news. Not only has the company been cagey in discussing its plans for
pivotal trials of its lead drug CYT387, but partnership discussions have
supposedly been ongoing for most of the year so far. While I'm
cautiously optimistic that YM Biosciences does have a real winner in
myelofibrosis, it may well be hard for this stock to outperform without
the seal of approval represented by a Big Pharma partner.
Please click here for more:
The Wait Goes On At YM Biosciences
No comments:
Post a Comment